Literature DB >> 10350185

Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.

H Yamazaki1, K Inoue, M Hashimoto, T Shimada.   

Abstract

Nicotine C-oxidation by recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes was investigated using a convenient high-performance liquid chromatographic method. Experiments with recombinant human P450 enzymes in baculovirus systems, which co-express human nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH)-P450 reductase, revealed that CYP2A6 had the highest nicotine C-oxidation activities followed by CYP2B6 and CYP2D6; the Km values by these three P450 enzymes were determined to be 11.0, 105, and 132 microM, respectively, and the Vmax values to be 11.0, 8.2, and 8.6 nmol/min per nmol P450, respectively. CYP2E1, 2C19, 1A2, 2C8, 3A4, 2C9, and 1A1 catalysed nicotine C-oxidation only at high (500 microM) substrate concentration. CYP1B1, 2C18, 3A5, and 4A11 had no measurable activities even at 500 microM nicotine. In liver microsomes of 16 human samples, nicotine C-oxidation activities were correlated with CYP2A6 contents at 10 microM substrate concentration, whereas such correlation coefficients were decreased when the substrate concentration was increased to 500 microM. Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 microM nicotine. CYP2D6 was found to have minor roles since quinidine did not inhibit microsomal nicotine C-oxidation at both 10 and 500 microM substrate concentrations. These results support the view that CYP2A6 has major roles for nicotine C-oxidation at lower substrate concentration and both CYP2A6 and 2B6 play roles at higher substrate concentrations in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350185     DOI: 10.1007/s002040050588

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  48 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity.

Authors:  Dongmei Li; Xiaoqin Huang; Keli Han; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2011-04-22       Impact factor: 15.419

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 4.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

5.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 6.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Allele and genotype frequencies of CYP2B6 in a Turkish population.

Authors:  Nazan Yuce-Artun; Gulcin Kose; H Sinan Suzen
Journal:  Mol Biol Rep       Date:  2014-02-22       Impact factor: 2.316

8.  Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse.

Authors:  Lei Li; Kunzhi Jia; Xin Zhou; Sarah E McCallum; Lindsay B Hough; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2013-09-17       Impact factor: 4.030

9.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

10.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.